Form 4 for IDXX Idexx Laboratories
Accepted 2024-02-09 00:00:00 ET · period of report 2024-02-07 · accession 0000874716-24-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-09 | 2024-02-07 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | S - Sale+OE | $572.61 | -12.0K | 81.8K | -13% | -$6.87M |
| D | 2024-02-09 | 2024-02-07 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $67.85 | +12.0K | 91.2K | +15% | +$814.2K |
| D | 2024-02-09 | 2024-02-07 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | — | -12.0K | 29.3K | -29% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-07 | S | D | 705 | $575.48 | 79,246.59 | D | — | — | (F6) Represents the weighted average price of the shares sold ranging from a low of $575.35 to a high of $575.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2024-02-07 | S | D | 1,353 | $574.75 | 79,951.59 | D | — | — | (F5) Represents the weighted average price of the shares sold ranging from a low of $574.29 to a high of $575.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 3 | Common | Common Stock | 2024-02-07 | S | D | 462 | $573.19 | 81,304.59 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $573.14 to a high of $573.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Common | Common Stock | 2024-02-07 | S | D | 5,356 | $571.71 | 85,890.59 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $571.12 to a high of $572.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 5 | Common | Common Stock | 2024-02-07 | M | A | 12,000 | $67.85 | 91,246.59 | D | — | — | (F1) Includes 13.247 shares purchased under the Issuer Employee Stock Purchase Plan on December 29, 2023. |
| 6 | Common | Common Stock | 2024-02-07 | S | D | 4,124 | $572.53 | 81,766.59 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $572.13 to a high of $573.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 7 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2024-02-07 | M | D | 12,000 | — | 29,260 | D | $67.85 · — to 2026-02-13 | 12,000 Common Stock | (F8) Not applicable. (F7) Grant of option to buy shares of Issuer common stock that became exercisable in four annual installments beginning February 14, 2017. |